What it is
Tesamorelin is a growth-hormone-releasing hormone analog. Egrifta products have a specific FDA-approved indication; catalog research material is not automatically equivalent.
Mechanism and research questions
- It acts through the GHRH axis to increase growth-hormone signaling.
- Clinical studies have evaluated specific body-composition and liver-fat endpoints in defined populations.
Human evidence
Trials have studied visceral fat and liver-fat endpoints, including in adults with HIV-associated lipodystrophy.
Preclinical / mechanistic evidence
Growth-hormone-axis pharmacology provides mechanistic context, not a general wellness claim.
Evidence summary
Clinical trials and FDA labeling exist, but the approved indication is narrow and should not be generalized to all uses.
Limits and interpretation
- FDA labeling is indication-specific.
- Approved pharmaceutical evidence does not validate research-vial equivalence.
- Warnings, contraindications, and monitoring requirements belong to the official label.
Regulatory and identity note
Tesamorelin has FDA-approved Egrifta products for a specific indication; this catalog listing remains research-use material.